TransMedics Group, Inc. (TMDX) shares are experiencing an uptick today, likely influenced by a recent policy change from the U.S. Department of Health and Human Services (HHS). On November 27, 2024, HHS announced the removal of clinical research requirements for kidney and liver transplants involving HIV-positive donors and recipients. This regulatory update is expected to expand the pool of available organs and streamline the transplantation process, potentially benefiting companies like TransMedics that are involved in organ transplant technologies. The policy change aligns with the Biden-Harris administration's efforts to increase access to life-saving organs and address health inequities, which could enhance the demand for TransMedics' Organ Care System (OCS) technology.
The stock is currently trading at $84.45, marking a 4.76% increase from its previous close of $80.61, and a 3.56% rise from the opening price of $81.55.